Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | SHBG | P04278 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 14/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4227246 | 0.74 | SHBG (0.53) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL11960923 | 0.74 | SHBG (0.53) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL12140987 | 0.74 | SHBG (0.53) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL4220412 | 0.74 | SHBG (0.53) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL9974502 | 0.72 | CYP3A4 (0.47) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL20277993 | 0.71 | CYP3A4 (0.39) | CYP3A4SHBG | |
| SCHEMBL16300025 | 0.68 | CYP3A4 (0.56) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL15195626 | 0.67 | SHBG (0.59) | CYP3A4SHBGTSHRTHPOHIF1A | |
| SCHEMBL11950764 | 0.67 | CYP3A4 (0.42) | CYP3A4SHBGCYP19A1 | |
| SCHEMBL6573096 | 0.67 | CYP3A4 (1.00) | CYP3A4SHBGTSHRTHPOHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | UNIVERSITAT DORTMUND (DE) | 2009-03-05 | — | — | US | disclosed |
| EP-1841723-A1 | DECALINE DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | Universität Dortmund (DE) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006069787-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | Universität Dortmund (DE) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062401-A1 | DECALINE-DERIVED COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS | CHAT, DLAT, CPT1A | CYP3A4 2291/4885SHBG 2547/4885TSHR 2761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.